Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
dc.contributor.author | Kolinsky, M. P. | |
dc.contributor.author | Roubaud, G. | |
dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
dc.contributor.author | Penel, N. | |
dc.contributor.author | Matsubara, N. | |
dc.contributor.author | Mehra, N. | |
dc.contributor.author | Procopio, G. | |
dc.contributor.author | Feyerabend, S. | |
dc.contributor.author | Joung, J. Y. | |
dc.contributor.author | Gravis, G. | |
dc.contributor.author | Nishimura, K. | |
dc.contributor.author | Gedye, C. | |
dc.contributor.author | Padua, C. | |
dc.contributor.author | Shore, N. | |
dc.contributor.author | Thiery-Vuillemin, A. | |
dc.contributor.author | Gresty, C. | |
dc.contributor.author | Brickel, N. | |
dc.contributor.author | Burgents, J. | |
dc.contributor.author | Allen, A. | |
dc.contributor.author | Fizazi, K. | |
dc.date.accessioned | 2021-03-02T17:07:06Z | |
dc.date.available | 2021-03-02T17:07:06Z | |
dc.identifier.citation | Roubaud G., ÖZGÜROĞLU M., Penel N., Matsubara N., Mehra N., Kolinsky M. P. , Procopio G., Feyerabend S., Joung J. Y. , Gravis G., et al., "Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 | |
dc.identifier.other | av_9f0f7fcd-6c33-4d62-bf26-256d93e82eb0 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/3575 | |
dc.identifier.uri | https://doi.org/10.1016/j.annonc.2020.08.883 | |
dc.language.iso | eng | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.title | Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound | |
dc.type | Bildiri | |
dc.contributor.department | UNICANCER , , | |
dc.identifier.volume | 31 | |
dc.contributor.firstauthorID | 2286927 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Bildiri [64839]